The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Detection and prognostic relevance of circulating tumour cells (CTCs) in Asian breast cancers using a label-free microfluidic platform
Open accessAbstract
OBJECTIVES: We aimed to study the prevalence of CTCs in breast cancer (BC) patients undergoing neoadjuvant or palliative therapy with a label-free microfluidic platform (ClearCell FX), and its prognostic relevance in metastatic BC (mBC). MATERIALS AND METHODS: Peripheral blood samples were collected from 108 BC patients before starting a new line of treatment ("baseline"), majority of whom had mBC (76/108; 70.4%). CTCs were retrieved by dean flow fractionation that enriched for larger cells, and enumerated using immunofluorescence-based staining. Progression-free survival (PFS) in mBC patients was analysed using Kaplan-Meier method; cox proportional hazard models were used for univariable and multivariable analyses. RESULTS: The detection rate of CTCs before starting a new line of treatment was 75.9% (n = 108; median: 8 CTCs/7.5 ml blood) at a cut off of ≥2 CTCs. PFS was inferior for mBC patients with baseline CTC count ≥5 CTCs/7.5 ml blood vs. those with < 5 CTCs/7.5 ml blood (median PFS: 4.3 vs. 7.0 months; p-value: 0.037). The prognostic relevance of CTCs was most significant in patients with HER2- mBC (median PFS: 4.1 vs. 8.3 months; p-value: 0.032), luminal (HR+HER2-) subtype (median PFS: 4.2 vs. 8.3 months; p-value: 0.048), and patients who had one or more prior treatments (median PFS: 4.2 vs. 7.0 months; p-value: 0.02). On multivariable analysis, baseline CTC level (hazard ratio (HR): 1.84, p-value: 0.02) and pre-treatment status (HR: 1.87, p-value: 0.05) were independent predictors of PFS. CONCLUSIONS: This work demonstrates the prognostic significance of CTCs in mBC detected using a label-free size-based enrichment platform.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These cells are precise representations of primary and metastatic tumors that convey information for the detection, diagnosis (monitoring) and the treatment of cancer [145].”
From Tumor microenvironment complexity and therapeutic implications at a glance (2020) · cites this paper as [145]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer
Cristofanilli, M., Budd, G. T., Ellis, M. J., Stopeck, A., Matera, J., Miller, M. C., Reuben, J. M., Doyle, G. V., Allard, W. J., Terstappen, L. W. M. M., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040766 · Cited by 4,593 · cited 4×
“Long-term patient outcomes are influenced by biological risk factors such as cancer subtypes, the extent and site of metastatic lesion, and the level of circulating tumour cells (CTCs) [1, 2].”
BackgroundResultInfluentialHammond, M. E. H., Hayes, D. F., Dowsett, M., Allred, D. C., Hagerty, K. L., Badve, S., Fitzgibbons, P. L., Francis, G., Goldstein, N. S., Hayes, M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.6529 · Cited by 4,213
Wolff, A. C., Hammond, M. E. H., Hicks, D. G., Dowsett, M., McShane, L. M., Allison, K. H., Allred, D. C., Bartlett, J. M. S., Bilous, M., Fitzgibbons, P., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.50.9984 · Cited by 4,030 · cited 2×
“The determination of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) status by immunohistochemistry in this study was based on the latest recommendations by the American Society of Clinical Oncology and the College of American Pathologists.”
MethodAllard, W. J., Matera, J., Miller, M. C., Repollet, M., Connelly, M. C., Rao, C., Tibbe, A. G. J., Uhr, J. W., & Terstappen, L. W. M. M. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0378 · Cited by 2,542
Circulating Breast Tumor Cells Exhibit Dynamic Changes in Epithelial and Mesenchymal Composition
Yu, M., Bardia, A., Wittner, B. S., Stott, S. L., Smas, M. E., Ting, D. T., Isakoff, S. J., Ciciliano, J. C., Wells, M. N., Shah, A. M., et al. (2013) · Science · doi:10.1126/science.1228522 · Cited by 2,476 · cited 3×
“EMT has been widely described in BC [14] and elevated level of mesenchymal-like CTCs has been associated with treatment failure [15].”
BackgroundCirculating Tumor Cells: A Novel Prognostic Factor for Newly Diagnosed Metastatic Breast Cancer
Cristofanilli, M., Hayes, D. F., Budd, G. T., Ellis, M. J., Stopeck, A., Reuben, J. M., Doyle, G. V., Matera, J., Allard, W. J., Miller, M. C., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.08.140 · Cited by 1,135 · cited 1×
“Subsequent studies further confirmed that high CTC levels in patients who had undergone treatment predicted the risk of metastatic spread [3, 4].”
BackgroundHammond, M. E. H., Hayes, D. F., Dowsett, M., Allred, D. C., Hagerty, K. L., Badve, S., Fitzgibbons, P. L., Francis, G., Goldstein, N. S., Hayes, M., et al. (2010) · Archives of Pathology & Laboratory Medicine · doi:10.5858/134.7.e48 · Cited by 1,042
Hayes, D. F., Cristofanilli, M., Budd, G. T., Ellis, M. J., Stopeck, A., Miller, M. C., Matera, J., Allard, W. J., Doyle, G. V., & Terstappen, L. W. W. M. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2821 · Cited by 1,030
Hammond, M. E. H., Hayes, D. F., Dowsett, M., Allred, D. C., Hagerty, K. L., Badve, S., Fitzgibbons, P. L., Francis, G., Goldstein, N. S., Hayes, M., et al. (2010) · Archives of Pathology & Laboratory Medicine · doi:10.5858/134.6.907 · Cited by 895
Isolation and retrieval of circulating tumor cells using centrifugal forces
Hou, H. W., Warkiani, M. E., Khoo, B. L., Li, Z. R., Soo, R. A., Tan, D. S.-W., Lim, W.-T., Han, J., Bhagat, A. A. S., & Lim, C. T. (2013) · Scientific Reports · doi:10.1038/srep01259 · Cited by 736 · cited 1×
“Briefly, within a proprietary spiral microfluidic chip, Dean drag forces will cause smaller hematologic cells (leukocytes) to migrate along the Dean vortices towards the inner wall of the spiral channels, then back to outer wall again, while the larger CTCs experience additional strong inertial lift forces that will f…”
BackgroundSelf-citationCirculating tumour cells in non-metastatic breast cancer: a prospective study
Lucci, A., Hall, C. S., Lodhi, A. K., Bhattacharyya, A., Anderson, A. E., Xiao, L., Bedrosian, I., Kuerer, H. M., & Krishnamurthy, S. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70209-7 · Cited by 507
Circulating Tumor Cells: A Useful Predictor of Treatment Efficacy in Metastatic Breast Cancer
Liu, M. C., Shields, P. G., Warren, R. D., Cohen, P., Wilkinson, M., Ottaviano, Y. L., Rao, S. B., Eng-Wong, J., Seillier-Moiseiwitsch, F., Noone, A.-M., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.6664 · Cited by 319
Bidard, F.-C., Fehm, T., Ignatiadis, M., Smerage, J. B., Alix-Panabières, C., Janni, W., Messina, C., Paoletti, C., Müller, V., Hayes, D. F., et al. (2013) · Cancer and Metastasis Reviews · doi:10.1007/s10555-012-9398-0 · Cited by 237
Circulating Tumor Cells: A Review of Non–EpCAM-Based Approaches for Cell Enrichment and Isolation
Gabriel, M. T., Calleja, L. R., Chalopin, A., Ory, B., & Heymann, D. (2016) · Clinical Chemistry · doi:10.1373/clinchem.2015.249706 · Cited by 237
Single circulating tumor cell detection and overall survival in nonmetastatic breast cancer
Bidard, F.-C., Mathiot, C., Delaloge, S., Brain, E., Giachetti, S., de Cremoux, P., Marty, M., & Pierga, J.-Y. (2010) · Annals of Oncology · doi:10.1093/annonc/mdp391 · Cited by 232
Giordano, A., Gao, H., Anfossi, S., Cohen, E., Mego, M., Lee, B.-N., Tin, S., De Laurentiis, M., Parker, C. A., Alvarez, R. H., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0460 · Cited by 219 · cited 1×
“Lastly, the molecular features of CTCs may have shifted to a mesenchymal or basal-like subtype, which means that the use of epithelial detection markers may underestimate the actual CTC numbers in the triple-negative cohort and HER2+ patients [14, 38, 41].”
BackgroundGiuliano, M., Giordano, A., Jackson, S., Hess, K. R., De Giorgi, U., Mego, M., Handy, B. C., Ueno, N. T., Alvarez, R. H., De Laurentiis, M., et al. (2011) · Breast Cancer Research · doi:10.1186/bcr2907 · Cited by 217
Khoo, B. L., Warkiani, M. E., Tan, D. S.-W., Bhagat, A. A. S., Irwin, D., Lau, D. P., Lim, A. S. T., Lim, K. H., Krisna, S. S., Lim, W.-T., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0099409 · Cited by 206 · cited 1×
“The method enriches for CTCs via dean flow fractionation to separate the larger CTCs from smaller blood cells [19, 23].”
MethodSelf-citationTewes, M., Aktas, B., Welt, A., Mueller, S., Hauch, S., Kimmig, R., & Kasimir-Bauer, S. (2009) · Breast Cancer Research and Treatment · doi:10.1007/s10549-008-0143-x · Cited by 203 · cited 1×
“Long-term patient outcomes are influenced by biological risk factors such as cancer subtypes, the extent and site of metastatic lesion, and the level of circulating tumour cells (CTCs) [1, 2].”
BackgroundHER2-Positive Circulating Tumor Cells in Breast Cancer
Ignatiadis, M., Rothé, F., Chaboteaux, C., Durbecq, V., Rouas, G., Criscitiello, C., Metallo, J., Kheddoumi, N., Singhal, S. K., Michiels, S., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0015624 · Cited by 203
Tumor Dissemination: An EMT Affair
Thiery, J. P., & Lim, C. T. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.03.004 · Cited by 194
Babayan, A., Hannemann, J., Spötter, J., Müller, V., Pantel, K., & Joosse, S. A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0075038 · Cited by 129 · cited 1×
“of either EpCAM or cytokeratin and negative CD45 expression was classified as a circulating tumour cell.[10] A schematic of the workflow is illustrated in S1 Fig.”
MethodGiuliano, M., Giordano, A., Jackson, S. A., Giorgi, U. D., Mego, M., Cohen, E. N., Gao, H., Anfossi, S., Handy, B. C., Ueno, N. T., et al. (2014) · Breast Cancer Research · doi:10.1186/s13058-014-0440-8 · Cited by 124 · cited 2×
“Results from earlier studies also suggest CTC burden as a predictor of metastatic potential, and potentially a higher visceral tumour burden [4].”
BackgroundResultLee, Y., Guan, G., & Bhagat, A. A. S. (2018) · Cytometry Part A · doi:10.1002/cyto.a.23507 · Cited by 122
Self-citationGiordano, A., Giuliano, M., Laurentiis, M. D., Arpino, G., Jackson, S. A., Handy, B. C., Ueno, N. T., Andreopoulou, E., Alvarez, R. H., Valero, V., et al. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr434 · Cited by 110
Detection of Activating Estrogen Receptor Gene ( ESR1 ) Mutations in Single Circulating Tumor Cells
Paolillo, C., Mu, Z., Rossi, G., Schiewer, M. J., Nguyen, T., Austin, L., Capoluongo, E., Knudsen, K. E., Cristofanilli, M., & Fortina, P. M. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1173 · Cited by 85
Wallwiener, M., Hartkopf, A. D., Riethdorf, S., Nees, J., Sprick, M. R., Schönfisch, B., Taran, F., Heil, J., Sohn, C., Pantel, K., et al. (2015) · BMC Cancer · doi:10.1186/s12885-015-1423-6 · Cited by 83
Lv, Q., Gong, L., Zhang, T., Ye, J., Chai, L., Ni, C., & Mao, Y. (2015) · Clinical & Translational Oncology · doi:10.1007/s12094-015-1372-1 · Cited by 76
Peeters, D. J. E., van Dam, P.-J., den Eynden, G. G. V., Rutten, A., Wuyts, H., Pouillon, L., Peeters, M., Pauwels, P., Laere, S. V., van Dam, P. A., et al. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.743 · Cited by 76 · cited 2×
“Lastly, the molecular features of CTCs may have shifted to a mesenchymal or basal-like subtype, which means that the use of epithelial detection markers may underestimate the actual CTC numbers in the triple-negative cohort and HER2+ patients [14, 38, 41].”
BackgroundResultPierga, J., Bidard, F., Autret, A., Petit, T., André, F., Dalenc, F., Lévy, C., Ferrero, J.-M., Romieu, G., Bonneterre, J. M., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw535 · Cited by 74
Tan, C. L., Lim, T. H., Lim, T. K., Tan, D. S.-W., Chua, Y. W., Ang, M., Pang, B., Lim, C. T., Takano, A. M. P., Lim, W., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.8136 · Cited by 72
Self-citationWong, N. S., Kahn, H. J., Zhang, L., Oldfield, S., Yang, L., Marks, A., & Trudeau, M. (2006) · Breast Cancer Research and Treatment · doi:10.1007/s10549-006-9181-4 · Cited by 67
Circulating Breast Tumor Cells Exhibit Dynamic Changes in Epithelial and Mesenchymal Composition
Barsan, V. V., Cristofanilli, M., & Mani, S. A. (2013) · Breast Diseases A Year Book Quarterly · doi:10.1016/j.breastdis.2013.07.021 · Cited by 66
Kalinsky, K. M., Mayer, J., Xu, X., Pham, T., Wong, K. L., Villarin, E., Pircher, T. J., Brown, M., Maurer, M., & Bischoff, F. Z. (2015) · Clinical & Translational Oncology · doi:10.1007/s12094-015-1275-1 · Cited by 55
Paoletti, C., Larios, J. M., Muñiz, M. C., Aung, K., Cannell, E. M., Darga, E. P., Kidwell, K., Thomas, D. G., Tokudome, N., Brown, M. E., et al. (2016) · Molecular Oncology · doi:10.1016/j.molonc.2016.04.006 · Cited by 49 · cited 1×
“A second possibility could be that CTCs reflect a transition of the tumour to increased aggressiveness and drug resistance in the HR+/HER2- subtype; for example, by the development of endocrine resistance with ESR1 mutations [39, 40].”
BackgroundCirculating tumor cells in newly diagnosed inflammatory breast cancer
Mego, M., Giordano, A., Giorgi, U. D., Masuda, H., Hsu, L., Giuliano, M., Fouad, T. M., Dawood, S. S., Ueno, N. T., Valero, V., et al. (2015) · Breast Cancer Research · doi:10.1186/s13058-014-0507-6 · Cited by 47
Mitosis in circulating tumor cells stratifies highly aggressive breast carcinomas
Adams, D. L., Adams, D. K., Stefansson, S., Haudenschild, C., Martin, S. S., Charpentier, M., Chumsri, S., Cristofanilli, M., Tang, C.-M., & Alpaugh, R. K. (2016) · Breast Cancer Research · doi:10.1186/s13058-016-0706-4 · Cited by 40
Circulating tumor cells in non-metastatic triple-negative breast cancer
Karhade, M., Hall, C. S., Mishra, P., Anderson, A. E., Kuerer, H. M., Bedrosian, I., Krishnamurthy, S., & Lucci, A. (2014) · Breast Cancer Research and Treatment · doi:10.1007/s10549-014-3103-7 · Cited by 36
Sawada, T., Araki, J., Yamashita, T., Masubuchi, M., Chiyoda, T., Yunokawa, M., Hoshi, K., Tao, S., Yamamura, S., Yatsushiro, S., et al. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2016.07.027 · Cited by 24
Wong, V. C.-L., Ko, J. M. Y., Lam, C.-T., & Lung, M. L. (2017) · PLoS ONE · doi:10.1371/journal.pone.0177276 · Cited by 15
Horiguchi, J., Takata, D., Rokutanda, N., Nagaoka, R., TOKINIWA, H., Tozuka, K., Sato, A., Kikuchi, M., Oyama, T., & Takeyoshi, I. (2012) · Cancer Research · doi:10.1158/0008-5472.sabcs12-p3-06-29 · Cited by 5
Bidard, F., Romieu, G., Jacot, W., Cottu, P. H., Dieras, V. C., Lerebours, F., Servent, V., Luporsi, É., Lortholary, A. H., Tubiana-Mathieu, N., et al. (2016) · Cancer Research · doi:10.1158/1538-7445.sabcs15-p2-02-17 · Cited by 4
Fraser-Fish, J., Ahmad, Z., Kumar, R., Ebbs, B., Fowler, G., Flohr, P., Crespo, M., Ahmed, M., Popat, S., Bhosle, J., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw363.24 · Cited by 3
Bidard, F., Rycke, Y. D., Asselain, B. J. R., Dieras, V. C., Lebofsky, R., & Pierga, J. (2013) · Cancer Research · doi:10.1158/0008-5472.sabcs13-ot1-1-10 · Cited by 1
Cited by
Tumor microenvironment complexity and therapeutic implications at a glance
Baghban, R., Roshangar, L., Jahanban-Esfahlan, R., Seidi, K., Ebrahimi-Kalan, A., Jaymand, M., Kolahian, S., Javaheri, T., & Zare, P. (2020) · Cell Communication and Signaling · doi:10.1186/s12964-020-0530-4 · Cited by 1,784
“These cells are precise representations of primary and metastatic tumors that convey information for the detection, diagnosis (monitoring) and the treatment of cancer [145] .”
BackgroundA Review of Circulating Tumour Cell Enrichment Technologies
Rushton, A. J., Nteliopoulos, G., Shaw, J. A., & Coombes, R. C. (2021) · Cancers · doi:10.3390/cancers13050970 · Cited by 197
“The ClearCell FX1 platform (Biolidics, Singapore) is a spiral microfluidic device which uses Dean Flow Fractionation (DFF) principles (dean forces and lift forces) to focus and retain larger CTCs at the inner side of the spiral channel whilst the remaining blood components flow through the chip via the outer side of t…”
BackgroundMethodInfluentialCirculating Tumor Cells in Early and Advanced Breast Cancer; Biology and Prognostic Value
Fabisiewicz, A., Szostakowska-Rodzoś, M., Zaczek, A. J., & Grzybowska, E. A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21051671 · Cited by 80
Heterogeneity of Circulating Tumor Cells in Breast Cancer: Identifying Metastatic Seeds
Menyailo, M. E., Tretyakova, M. S., & Denisov, E. V. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21051696 · Cited by 79
“Several studies reported that CTCs can be observed in non-cancer volunteers [28,29]; however, its number is extremely rare and can be a false-positive rate of the used CTC detection methods.”
Liu, Y., Yan, X. S., Chen, J., Zhan, Q., Hua, Y., Xu, S., Li, Z., Wang, Z., Dong, Y., Zuo, D., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2012228118 · Cited by 72
Metadata
- Authors
- Yap, Y.-S., Leong, M. C., Chua, Y. W., Loh, K. W. J., Lee, G. E., Lim, E. H., Dent, R., Ng, R. C. H., Lim, J. H.-C., Singh, G., Tan, A., Guan, G., Wu, A., Lee, Y. F., Bhagat, A. A. S., & Lim, D. W.-T.
- Affiliations
- National Cancer Centre Singapore (SG)
- Singapore General Hospital (SG)
- Agency for Science, Technology and Research (SG)
- Corresponding author
- Yap, Yoon-Sim
- ORCID
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2019-09-25
- Volume
- 14
- Issue
- 9
- Pages
- e0221305
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC6760773
- OpenAlex
- W2976283796
- Cited by
- 23
- References
- 44
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 2 · 2023: 5 · 2022: 3 · 2021: 3 · 2020: 6
- FWCI
- 0.95
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- National University of Singapore (submittedVersion)
- Funders
- National Cancer Centre of Singapore
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Keywords
- circulating tumor cells, breast cancer, metastatic breast cancer, prognostic factors, progression-free survival, HER2-negative breast cancer, luminal breast cancer, Asian patients, neoadjuvant therapy, palliative care
- MeSH terms
- Progression-Free Survival, Adult, Aged, Breast Neoplasms, Cell Count, Female, Humans, Immunohistochemistry, Middle Aged, Neoplastic Cells, Circulating, Prognosis, Prospective Studies, Singapore, Erb-b2 Receptor Tyrosine Kinases, Receptor, ErbB-2, Microfluidics, Asian People, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.